Qingxia Fan

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Jin Lü, Yuxian Bai, Teng Mao et al. · JAMA · 2021 · 801 citations · Full text

Medicine, Oncology, Pharmacology +17

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

Jing Huang, Jianming Xu, Yun Chen et al. · The Lancet Oncology · 2020 · 584 citations

Medicine, Oncology, Pharmacology +14

Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study

Zhi Peng, Tianshu Liu, Jia Wei et al. · Cancer Communications · 2021 · 202 citations · Full text

Medicine, Oncology, Pharmacology +16

Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)

Jianming Xu, Yi Li, Qingxia Fan et al. · Nature Communications · 2022 · 150 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors

Yingying Xu, Yakun Wang, Jifang Gong et al. · Gastric Cancer · 2021 · 149 citations · Full text

Medicine, Oncology, Pharmacology +17